Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
Home / Learn / Immunotherapy / Resource Detail

[Abstract 98 (245555)] Planning for Survivorship After Checkpoint Inhibitors

  February 28, 2019

Authors: Tara Perloff, Monique Dawkins, Mary Hurd, Jennifer Wang, Sigrun Hallmeyer; Association of Community Cancer Centers, Rockville, MD; Advocate Lutheran General Hospital, Park Ridge, IL; Oncology Specialists, SC, Park Ridge, IL

Background: Survivorship care plans are a key piece of coordinated, patient-centered care delivery. As with other cancer treatment modalities, patients with metastatic disease who achieve durable benefit with immunotherapy (IO) treatment may experience late physical and psychosocial effects which can negatively impact quality of life. An online education program was created to educate the multidisciplinary cancer care team on the nuances related to survivorship for patients who are treated with checkpoint inhibitors. 

Methods: A medical oncologist, oncology nurse, oncology social worker and patient developed a curriculum to identify challenges and solutions for survivorship care planning, prepare care teams for nuances related to survivorship for IO patients, and optimize coordination and communication between the care team and the patient. In June 2018, a live-online 1-hour webcast that included a panel discussion with presentation slides, participant polling, and live ‘ask the panel’ questions was produced and made available on-demand. 

Results: A total of 149 learners viewed the webcast; 86 of these learners participated in the live webinar and 63 watched on-demand. To date, an estimated 590 patients per month are impacted by this education. Learners were actively engaged for an average of 35 minutes (out of 52 minutes). Most learners indicated specializing in oncology (49%), were practicing physicians (39%), and saw 1-10 new patients on an IO therapy each week (59%) in a hospital-based setting (42%). Due to the education provided, learners reported improvements in their ability to identify challenges and solutions for IO survivorship care planning (97%) and handle nuances related to survivorship for patients on cancer immunotherapies (88%). Learners also demonstrated improved comprehension via case study by identifying the most common, concerning side-effect for a high-risk melanoma patient treated with ipilimumab and nivolumab. 

Conclusions: Continued refinement of care coordination practices related to survivorship is recommended to improve the long-term management of patients who are treated with checkpoint inhibitors.

Download Poster